1887
Surveillance and outbreak report Open Access
Like 0

Abstract

Enhanced safety surveillance (ESS) was conducted in the United Kingdom and Finland for Vaxigrip and Intanza 15 µg to comply with the European Medicines Agency interim guidance aimed to detect any potential increase in reactogenicity in near real time following the annual update of the influenza vaccine strain composition. This pilot passive ESS was established to strengthen safety monitoring by facilitating spontaneous vaccinee reports and estimating near real-time vaccinee exposure. The primary objective was to estimate the reporting rates of suspected adverse reactions (ARs) occurring within 7 days post vaccination during the northern hemisphere 2015/16 influenza season. Among the Vaxigrip vaccinees (n = 1,012), 32 (3.2%) reported a total of 122 suspected ARs, including 110 suspected ARs that occurred within 7 days post vaccination. Among the Intanza 15 µg vaccinees (n = 1,017), 31 (3.0%) reported a total of 114 suspected ARs, including 99 that occurred within 7 days post-vaccination. These results were consistent with the known safety profile of the two vaccines and did not show any change in reactogenicity or safety concerns. This passive ESS showed improved data reporting and demonstrated its suitability to health authorities’ requirements; further fine tuning of the methodology is under discussion between all stakeholders.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2017.22.18.30527
2017-05-04
2024-03-29
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2017.22.18.30527
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/22/18/eurosurv-22-30527-4.html?itemId=/content/10.2807/1560-7917.ES.2017.22.18.30527&mimeType=html&fmt=ahah

References

  1. Vaccines against influenza WHO position paper – November 2012. Wkly Epidemiol Rec. 2012;87(47):461-76. PMID: 23210147 
  2. Al-Awaidy S, Hamid S, Al Obaidani I, Al Baqlani S, Al Busaidi S, Bawikar S, et al. The burden of influenza-associated hospitalizations in Oman, January 2008-June 2013. PLoS One. 2015;10(12):e0144186.  https://doi.org/10.1371/journal.pone.0144186  PMID: 26642055 
  3. Russell CA, Jones TC, Barr IG, Cox NJ, Garten RJ, Gregory V, et al. Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine. 2008;26(Suppl 4):D31-4.  https://doi.org/10.1016/j.vaccine.2008.07.078  PMID: 19230156 
  4. Barr IG, McCauley J, Cox N, Daniels R, Engelhardt OG, Fukuda K, et al. Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009-2010 northern hemisphere season. Vaccine. 2010;28(5):1156-67.  https://doi.org/10.1016/j.vaccine.2009.11.043  PMID: 20004635 
  5. Pharmacovigilance Risk Assessment Committee (PRAC) [Internet]. Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU. London: European Medicines Agency. (EMA) 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/04/WC500165492.pdf
  6. Public Health England (PHE). Flu plan winter 2015/16. London: PHE; 2015. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/526143/Flu_Plan_Winter_2015_to_2016superseded.pdf
  7. National Institute for Health and Welfare (THL).National Immunization Programme NIP in Finland. Helsinki: THL; 2017. Available from: http://www.terveyskirjasto.fi/terveyskirjasto/ktl.mat?p_selaus=4698
  8. European Medicines Agency (EMA). Guideline on good pharmacovigilance practices: module VI – management and reporting of adverse reactions to medicinal products (revision 1). London: EMA; 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/09/WC500172402.pdf
  9. European Medicines Agency (EMA). Guideline on good pharmacovigilance practices (GVP): annex I – definitions (revision 3). London: EMA; 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500143294.pdf
  10. A guideline on Summary of Product Characteristics (SmPC). Revision 2. Brussels: European Commission; Sep 2009. Available from: http://ec.europa.eu/health/sites/health/files/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf
  11. Houdouin V, Lavis N, Meyzer C, Jeziorski E, Merlin E, Pinquier D, et al. Safety of the Northern Hemisphere 2014/2015 formulation of the inactivated split-virion intramuscular trivalent influenza vaccine. Vaccine Reports. 2016;6:1-7.
  12. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). ENCePP guide on methodological standards in pharmacoepidemiology. Chapter 1: General aspects of study protocol. London: European Medicines Agency. [Accessed: 29 Mar 2016]. Available from: http://www.encepp.eu/standards_and_guidances/methodologicalGuide1.shtml
  13. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). ENCePP guide on methodological standards in pharmacoepidemiology. Chapter 6: Quality control and quality assurance. London: European Medicines Agency. [Accessed: 29 Mar 2016]. Available from: http://www.encepp.eu/standards_and_guidances/methodologicalGuide6.shtml
  14. Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001. MMWR Surveill Summ. 2003;52(1):1-24. PMID: 12825543 
  15. Vellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine. 2009;27(15):2114-20.  https://doi.org/10.1016/j.vaccine.2009.01.125  PMID: 19356614 
  16. Mahajan D, Roomiani I, Gold MS, Lawrence GL, McIntyre PB, Menzies RI. Annual report: surveillance of adverse events following immunisation in Australia, 2009. Commun Dis Intell Q Rep. 2010;34(3):259-76. PMID: 21090181 
  17. Vellozzi C, Broder KR, Haber P, Guh A, Nguyen M, Cano M, et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. Vaccine. 2010;28(45):7248-55.  https://doi.org/10.1016/j.vaccine.2010.09.021  PMID: 20850534 
  18. Liang XF, Li L, Liu DW, Li KL, Wu WD, Zhu BP, et al. Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China. N Engl J Med. 2011;364(7):638-47.  https://doi.org/10.1056/NEJMoa1008553  PMID: 21288090 
  19. Alguacil Ramos AM, Lluch Rodrigo JA, Portero Alonso A, Martín Ivorra R, Pastor Villalba E. [Variability in the reporting of adverse reactions to the pandemic and seasonal influenza vaccine: seasons 2009-2010 and 2010-2011. Valencian community, Spain]. Rev Esp Salud Publica. 2012;86(3):241-51.  https://doi.org/10.1590/S1135-57272012000300004  PMID: 22991081 
  20. Clothier HJ, Crawford NW, Kempe A, Buttery JP. Surveillance of adverse events following immunisation: the model of SAEFVIC, Victoria. Commun Dis Intell Q Rep. 2011;35(4):294-8. PMID: 22624490 
  21. Clothier HJ, Hosking L, Crawford NW, Russell M, Easton ML, Quinn JA, et al. Bacillus Calmette-Guérin (BCG) vaccine adverse events in Victoria, Australia: analysis of reports to an enhanced passive surveillance system. Drug Saf. 2015;38(1):79-86.  https://doi.org/10.1007/s40264-014-0248-6  PMID: 25475539 
  22. Routledge PA, O’Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol. 2004;57(2):121-6. </jrn> https://doi.org/10.1046/j.1365-2125.2003.01875.x  PMID: 14748810 
/content/10.2807/1560-7917.ES.2017.22.18.30527
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error